dual gip/glp-1 receptor agonist Understand GLP-1/GIP Tirzepatide and Its Effect on Current Weight Loss Therapy Polyagonists Enable Increasingly Effective Treatment
Description
d For the GLP-1 RA component only
Nevertheless, CCK continues to be studied as a possible therapeutic candidate for weight loss
Safety & Medical Monitoring Understanding Potential Risks & Side Effects Responsible treatment involves understanding possible side effects and knowing when to seek help
has received research funding from NHMRC, Diabetes Australia, Novartis, and Sanofi
32260-8/asset/b3e92579-8c29-4267-895b-56d26c1d4c0b/main.assets/gr3_lrg.jpg)
Lancet (1966) 2:7279
The renoprotective effect of GLP-1RA can be achieved by reducing urinary protein levels and the glomerular filtration rate (66, 67)
